The National Institute of Allergy and Infectious Diseases (NIAID) has begun a phase 2 study of the potential of approved therapies and late-stage investigational drugs for hospitalized COVID-19 patients. Read More
Moderna has slowed enrollment of its phase 3 COVID-19 vaccine trial because it is experiencing challenges recruiting enough Black, Latino and Native American participants. The Cambridge, Mass.-based biotech company suggests this lack of diversity is preventing researchers from understanding how its COVID-19 vaccine candidate works in minority populations. Read More
A new guideline from the European Medicines Agency (EMA) provides recommendations on how data monitoring committees (DMC) should proceed when considering stopping a trial. Read More
Dozens of medical experts from across the nation have written a letter to FDA Commissioner Stephen Hahn, Center for Biologics Evaluation and Research (CBER) Director Peter Marks and the FDA’s vaccine advisory committee calling for stronger requirements for monitoring participants in COVID-19 vaccine trials. Read More
The National Institute of Allergy and Infectious Diseases (NIAID) has partnered with Matrix Medical Network to help more than 20 academic medical centers involved in NIAID’s COVID-19 Prevention Network establish mobile health clinics at universities, hospitals and other locations across the U.S. Read More
The first wave of COVID-19 vaccine development has not monitored the response of T cells to the virus, a missed opportunity that should be addressed in the next wave of COVID-19 research, two experts said last week. Read More
AstraZeneca (AZ) has released the trial protocol for the late-stage study of its coronavirus vaccine candidate AZD1222 as its investigation into an adverse event continues. Read More
RSS
